Maxcyte (MXCT) Debt to Equity (2020)

Maxcyte (MXCT) reported Debt to Equity of $0.15 for Q4 2020.

Maxcyte (MXCT) Debt to Equity (2020) Analysis & Trends

Maxcyte (MXCT) has 1 years of Debt to Equity data on file, last reported at $0.15 in Q4 2020.

Debt to Equity for Q4 2020 came in at $0.15, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $0.15 (changed N/A YoY), and the FY2020 annual result was $0.15, changed N/A from the prior year.
Debt to Equity held at $0.15 in Q4 2020 per MXCT's latest filing.
Over five years, Debt to Equity peaked at $0.15 in Q4 2020 and troughed at $0.15 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	0.65
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	0.64
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	0.57
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	0.06
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	0.95
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	0.27
10	Maxcyte	127.72 Mn	127.72 Mn	8.08 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	0.15